News Fresenius doubles down on biosimilars with big WuXi alliance Fresenius is already a player in the biosimilars market, and has ramped up its position via a deal with WuXi Bio that spans up to 37 candidates.
Digital Better analytics leads to fewer regulator questions Stronger data analytics is cutting the number of questions regulators ask about intensified processes.
News Sandoz says it is entering "golden decade" in biosimilars Sandoz said today it intends to double net sales between 2025 and 2035, fuelled by an acceleration in biosimilar medicine development.
News Sandoz adds 10 biosimilars through $322m Henlius deal Sandoz is set to add up to 10 new biosimilar assets to its portfolio under a new collaboration deal with China’s Shanghai Henlius Biotech.
Patients Sponsored 12 Questions with Kim Innes Kim Innes is General Manager of Teva UK. She has more than 30 years’ experience across the pharmaceutical industry.
News Sandoz will pay another $480m to settle US antitrust suits Sandoz has reached a settlement in the US that, if approved, could lay to rest years of litigation over price-fixing of generic medicines.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.